Codexis Announces Signing of Lease for GMP Manufacturing Facility

Core Insights - Codexis, Inc. has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California, marking a significant step in its transformation into a key development partner for enzymatic manufacturing of oligonucleotides [1][3] Company Developments - The new facility will enhance Codexis's internal capabilities for GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform, with modifications expected to begin in early 2026 [2] - The facility's flexible design will also support the scaling of high-quality purified enzymes, which are essential components of the ECO Synthesis platform [2] Strategic Vision - The establishment of this facility is seen as a pivotal move for Codexis, allowing the company to provide manufacturing services to customers for early clinical trials, thereby reinforcing its commitment to improving siRNA production quality and service [3] - The adaptability of the facility is intended to meet the evolving needs of the business, positioning Codexis as a full-service manufacturing technology innovator in the oligonucleotide sector [3][4]